Related Experiment Videos
Soluble glycoprotein 130 (gp130) attenuates OSM- and LIF-induced cartilage proteoglycan catabolism
1University Department of Medicine, University of Western Australia, Perth, Western Australia.
Abstract:
Oncostatin M (OSM) and leukaemia inhibitory factor (LIF) exhibit pleiotropic biological activities and share many structural and genetic features. The two cytokines bind with high affinity to the same receptor (LIF/OSM receptor), which consists of the LIF receptor alpha chain (LIFRalpha) and the signal transduction unit gp130. A soluble form of the beta chain of the receptor complex called soluble gp130 (sgp130) has been cloned. In this study, we sought to determine whether recombinant sgp130 or anti-gp130 Ab could attenuate the resorption of proteoglycans induced by OSM and LIF in articular cartilage explants. The results show that at high concentrations sgp130 is capable of attenuating both LIF and OSM mediated resorption. In contrast, anti-gp130 Ab selectively inhibited the stimulation of proteoglycan (PG) release by OSM, albeit minimally. The failure of anti-gp130 to attenuate LIF stimulated PG resorption may be due to the normal interaction of LIF with LIFRalpha and unfettered heterodimerization of LIFRalpha with gp130 in the presence of the antibody. The results indicate that sgp130 and anti-gp130 can modulate cartilage PG metabolism in vitro. Whether sgp130 may have therapeutic activity in models of arthritis or indeed in arthritic diseases remains to be determined.
Insights
Soluble gp130 (sgp130) can reduce proteoglycan resorption in cartilage stimulated by Oncostatin M (OSM) and leukemia inhibitory factor (LIF). Anti-gp130 antibodies showed limited inhibition, suggesting sgp130
Area of Science:
- Biochemistry and Molecular Biology
- Cell Biology
- Immunology
Background:
- Oncostatin M (OSM) and Leukemia Inhibitory Factor (LIF) are cytokines with shared structural and genetic features.
- Both OSM and LIF bind to the same receptor complex, comprising LIF receptor alpha chain (LIFRalpha) and gp130.
- A soluble form of gp130 (sgp130) has been developed.
Purpose of the Study:
- To investigate the potential of recombinant sgp130 and anti-gp130 antibodies to inhibit proteoglycan (PG) resorption induced by OSM and LIF in articular cartilage.
- To explore the differential effects of sgp130 and anti-gp130 on cytokine-mediated cartilage metabolism.
Main Methods:
- Articular cartilage explants were treated with OSM and LIF.
- Recombinant soluble gp130 (sgp130) and anti-gp130 antibodies were used to assess their inhibitory effects on PG resorption.
- Proteoglycan release was measured to quantify resorption.
Main Results:
- High concentrations of sgp130 effectively attenuated PG resorption induced by both LIF and OSM.
- Anti-gp130 antibodies demonstrated minimal and selective inhibition of OSM-stimulated PG release.
- LIF-stimulated PG resorption was not significantly inhibited by anti-gp130 antibodies, possibly due to unimpeded LIF-LIFRalpha interaction and gp130 heterodimerization.
Conclusions:
- Recombinant sgp130 and anti-gp130 antibodies can modulate cartilage proteoglycan metabolism in vitro.
- sgp130 shows promise in inhibiting cytokine-induced cartilage degradation.
- Further research is needed to determine the therapeutic potential of sgp130 in arthritis models and diseases.
Related Concept Videos
GPCR Desensitization
Matrix Proteoglycans and Glycoproteins
Proteoglycans
GPCRs Regulate Adenylyl Cylase Activity
Two...
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
TGF - β Signaling Pathway